
Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030
Description
Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030
The Generic Drugs Market size was estimated at USD 299.16 billion in 2023 and expected to reach USD 316.27 billion in 2024, at a CAGR 5.91% to reach USD 447.45 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aspen Holdings, Aurobindo Pharma, Baxter International Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin, Mylan Laboratories Limited, Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceuticals Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Simple Generic
Specialty Generic
Route of Administration
Inhalable
Injectable
Oral
Indication
Cancer
Cardiovascular Diseases
Central Nervous System Disorders
Diabetes
Gastrointestinal Diseases
Hormones & Related Diseases
Infectious Diseases
Respiratory Diseases
Distribution
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Generic Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Drugs Market?
3. What are the technology trends and regulatory frameworks in the Generic Drugs Market?
4. What is the market share of the leading vendors in the Generic Drugs Market?
5. Which modes and strategic moves are suitable for entering the Generic Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Generic Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
- 5.1.1.2. Favorable government approvals for generic drugs
- 5.1.1.3. Growing availability of generic drugs through online pharmacies
- 5.1.2. Restraints
- 5.1.2.1. Preference for branded drugs by patients and physicians
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D activities associated with generic drugs
- 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with quality and manufacturing variability
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Generic Drugs Market, by Type
- 6.1. Introduction
- 6.2. Simple Generic
- 6.3. Specialty Generic
- 7. Generic Drugs Market, by Route of Administration
- 7.1. Introduction
- 7.2. Inhalable
- 7.3. Injectable
- 7.4. Oral
- 8. Generic Drugs Market, by Indication
- 8.1. Introduction
- 8.2. Cancer
- 8.3. Cardiovascular Diseases
- 8.4. Central Nervous System Disorders
- 8.5. Diabetes
- 8.6. Gastrointestinal Diseases
- 8.7. Hormones & Related Diseases
- 8.8. Infectious Diseases
- 8.9. Respiratory Diseases
- 9. Generic Drugs Market, by Distribution
- 9.1. Introduction
- 9.2. Hospital Pharmacies
- 9.3. Online Pharmacies
- 9.4. Retail Pharmacies
- 10. Americas Generic Drugs Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Generic Drugs Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Generic Drugs Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Aspen Holdings
- 14.1.3. Aurobindo Pharma
- 14.1.4. Baxter International Inc.
- 14.1.5. Dr. Reddy’s Laboratories Ltd.
- 14.1.6. Eli Lilly and Company
- 14.1.7. Endo International plc.
- 14.1.8. Fresenius SE & Co. KGaA.
- 14.1.9. Gilead Sciences, Inc.
- 14.1.10. GlaxoSmithKline PLC
- 14.1.11. Glenmark Pharmaceuticals Ltd.
- 14.1.12. Hikma Pharmaceuticals PLC.
- 14.1.13. Johnson & Johnson Services, Inc.
- 14.1.14. Lupin
- 14.1.15. Mylan Laboratories Limited
- 14.1.16. Pfizer Inc.
- 14.1.17. Sandoz International GmbH by Novartis Group
- 14.1.18. Sanofi
- 14.1.19. STADA Arzneimittel AG
- 14.1.20. Sun Pharmaceutical Industries Ltd.
- 14.1.21. Teva Pharmaceuticals Industries Ltd.
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GENERIC DRUGS MARKET DYNAMICS
- FIGURE 7. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 10. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
- FIGURE 14. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.